未登录

T

Tina Sarén

department of immunology

H指数:6

被引数:105

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Pre-clinical safety and efficacy evaluation of Helicobacter Pylori neutrophil-activating protein (NAP)-armed CAR-T cells targeting B cell lymphomas

靶向B细胞淋巴瘤的幽门螺杆菌中性粒细胞活化蛋白(NAP)武装CAR-T细胞的临床前安全性和有效性评估

cancer immunology immunotherapy

IF0

2025-07-120

OA

Trogocytosis of chimeric antigen receptors between T cells is regulated by their transmembrane domains

T细胞间嵌合抗原受体的胞质吞噬作用由其跨膜结构域调控

SCIENCE IMMUNOLOGY

IF16.3

2025-01-311

PRE

Complementarity-determining region clustering may cause CAR-T cell dysfunction

NATURE COMMUNICATIONS

IF15.7

2023-08-1012

OAAI

Single-Cell RNA Analysis Reveals Cell-Intrinsic Functions of CAR T Cells Correlating with Response in a Phase II Study of Lymphoma Patients

CLINICAL CANCER RESEARCH

IF10.2

2023-08-043

OAAI

Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy (vol 22, 76, 2022)

IF3.5

2023-05-190

OAAI

Single-cell RNA analysis reveal effector-like CD8+ CAR-T cell subpopulations associated with response in lymphoma patients

CANCER RESEARCH

IF16.6

2023-04-040

PRE

Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy

IF3.5

2022-12-2713

OAAI

Tumor-Targeted Delivery of the p53-Activating Peptide VIP116 with PEG-Stabilized Lipodisks

IF4.3

2020-04-1916

OAAI

Insertion of the Type-I IFN Decoy Receptor B18R in a miRNA-Tagged Semliki Forest Virus Improves Oncolytic Capacity but Results in Neurotoxicity

MOLECULAR THERAPY-ONCOLYTICS

IF0

2017-12-016

OAAI